{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T07:11:37Z","timestamp":1718521897026},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,2,20]],"date-time":"2009-02-20T00:00:00Z","timestamp":1235088000000},"content-version":"vor","delay-in-days":50,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Dialysis"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment of anemia in dialysis patients improves patient well\u2010being and reduces the need for transfusions. Nevertheless, the hypothesis that normalization of hemoglobin via erythropoiesis\u2010stimulating agents (ESAs) would improve cardiovascular health and survival has largely been refuted by randomized trials showing increased cardiac events and mortality with higher Hgb targets and higher doses of ESAs. Given these observations, one would expect restraint in ESA use. However, profits for dialysis facilities depend greatly on charging insurers for medications, and ESAs are the most profitable. Consequently, for\u2010profit dialysis chains have an incentive to use high ESA doses. This practice was supported by the 2006 and 2007 Kidney Disease Outcomes Quality Initiative anemia guidelines; both versions promote higher hemoglobin targets and greater ESA use than the FDA and European Medicines Agency recommend. Under a Medicare bundled payment system in 2011, ESAs will move from being profitable to being an expense, and for\u2010profit dialysis centers will have motivation to reduce use of ESAs and other medications. Nephrologists, as caregivers and dialysis facility medical directors, have an ethical responsibility to protect the health and welfare of patients under all payment systems. This article reviews the financial and ethical issues involved in the treatment of dialysis\u2010related anemia and offers recommendations for maintaining ethical patient\u2010centered anemia management.<\/jats:p>","DOI":"10.1111\/j.1525-139x.2008.00531.x","type":"journal-article","created":{"date-parts":[[2009,2,16]],"date-time":"2009-02-16T14:36:31Z","timestamp":1234794991000},"page":"18-21","source":"Crossref","is-referenced-by-count":7,"title":["Ethical Issues in Dialysis\u2028Aaron Spital, Series Editor: Managing Anemia in For\u2010Profit Dialysis Chains: When Ethics and Business Conflict"],"prefix":"10.1111","volume":"22","author":[{"given":"Daniel W.","family":"Coyne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,20]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh1097"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000074938"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01050905"},{"key":"e_1_2_8_5_2","unstructured":"Dialysis Facility Compare. Available athttp:\/\/www.medicare.gov\/Dialysis\/Include\/DataSection\/Questions\/SearchCriteria.asp?version=default&browser=IE%7C6%7CWinXP&language=English&defaultstatus=0&pagelist=Home accessed May 19 2008"},{"key":"e_1_2_8_6_2","volume-title":"USRDS 2007 Annual Data Report: Atlas of End\u2010Stage Renal Disease in the United States","author":"System, URD","year":"2007"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390903"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062276"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065485"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2008.00423.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005090997"},{"key":"e_1_2_8_12_2","first-page":"S11","article-title":"Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","author":"KDOQI","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_8_13_2","unstructured":"Da Vita 1: DaVita Corporation:2007 Annual Report Form K\u201010 Securities and Exchange Commission. Flushing MI:DaVita Corporation 2008"},{"key":"e_1_2_8_14_2","unstructured":"Fresenius Medical Care:Annual Report Form 20\u2010F Securities and Exchange Commission. Waltham MA:Fresenius Medical Care 2007"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.15.1667"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02170606"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001875"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03130906"},{"key":"e_1_2_8_19_2","unstructured":"European Medicines Agency:Public Statement: Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease.2007"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.06.008"},{"key":"e_1_2_8_21_2","volume-title":"Epogen (Epoetin alfa)","year":"2008"}],"container-title":["Seminars in Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1525-139X.2008.00531.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1525-139X.2008.00531.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T19:37:33Z","timestamp":1697312253000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1525-139X.2008.00531.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1525-139X.2008.00531.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-139x.2008.00531.x","archive":["Portico"],"relation":{},"ISSN":["0894-0959","1525-139X"],"issn-type":[{"value":"0894-0959","type":"print"},{"value":"1525-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}